The most commonly reported side effects in clinical trials were gastrointestinal in nature , including nausea (24-30%), diarrhea (18-24%), vomiting (8-21%), constipation (16-17%), and abdominal pain (10-15%)
These therapies should be regarded as key components of larger cardiovascular risk reduction strategies, especially for individuals with established heart disease or type 2 diabetes, in addition to being used as treatments for glycaemic control
Stay upright after eating
[4] As a result, GLP-1 agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2 (MEN 2), a genetic disorder that increases the risk of certain types of tumors
Mechanisms of beta-cell apoptosis in type 2 diabetes-prone situations and potential protection by GLP-1-based therapies